secwatch.observer — SEC 8-K summary
======================================

Issuer:     Instil Bio, Inc. (TIL)
CIK:        0001789769
Form:       8-K
Filed at:   2024-05-10T23:59:59+00:00
Accession:  0001789769-24-000057
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Instil Bio reports Q1 net loss $3.74/share; cash runway beyond 2026
-------------------------------------------------------------------

- Cash, equivalents and investments of $161.5M at March 31, 2024; runway extends beyond 2026.
- Net loss per share (GAAP) $3.74 vs $8.77 YoY; non-GAAP loss per share $2.39 vs $4.29.
- R&D expenses fell to $7.3M from $20.7M; restructuring/impairment charges dropped to $4.3M.
- Preparing potential investigator-initiated trial of FRα-CoStAR TIL in non-small cell lung cancer.
- Company is exploring in-licensing or acquiring novel therapeutic candidates for unmet needs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789769/000178976924000057/0001789769-24-000057-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789769/000178976924000057/til-20240510.htm
  HTML page:      https://secwatch.observer/filing/0001789769-24-000057

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer